Latest Immunohistochemistry Stories
Miraca Life Sciences continues its commitment to the evolution of molecular testing by expanding diagnostic analysis with HER2 testing. IRVING, Texas (PRWEB)
ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC).
Over the last twelve years, Visiopharm has worked closely with leading Danish and International cancer researchers and pathologists to develop diagnostic software capable of improving and standardizing
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months.
- totally perplexed and mixed up.